Biogen (BIIB) Competitors $128.00 -2.67 (-2.04%) Closing price 08/11/2025 04:00 PM EasternExtended Trading$128.15 +0.15 (+0.11%) As of 05:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIIB vs. AMGN, GILD, IONS, MRNA, PRTA, SAVA, VRTX, ABBV, BMY, and LLYShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Amgen (AMGN), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Moderna (MRNA), Prothena (PRTA), Cassava Sciences (SAVA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Bristol Myers Squibb (BMY), and Eli Lilly and Company (LLY). These companies are all part of the "medical" sector. Biogen vs. Its Competitors Amgen Gilead Sciences Ionis Pharmaceuticals Moderna Prothena Cassava Sciences Vertex Pharmaceuticals AbbVie Bristol Myers Squibb Eli Lilly and Company Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation. Do institutionals & insiders believe in BIIB or AMGN? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.2% of Biogen shares are owned by company insiders. Comparatively, 0.7% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is BIIB or AMGN more profitable? Amgen has a net margin of 18.96% compared to Biogen's net margin of 15.31%. Amgen's return on equity of 174.71% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Amgen 18.96%174.71%13.12% Which has stronger earnings and valuation, BIIB or AMGN? Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B1.94$1.63B$10.4612.24Amgen$33.42B4.59$4.09B$12.2323.31 Which has more volatility & risk, BIIB or AMGN? Biogen has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Does the media prefer BIIB or AMGN? In the previous week, Amgen had 69 more articles in the media than Biogen. MarketBeat recorded 102 mentions for Amgen and 33 mentions for Biogen. Amgen's average media sentiment score of 0.93 beat Biogen's score of 0.72 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 17 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 61 Very Positive mention(s) 7 Positive mention(s) 11 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts rate BIIB or AMGN? Biogen presently has a consensus target price of $185.63, indicating a potential upside of 45.02%. Amgen has a consensus target price of $303.76, indicating a potential upside of 6.55%. Given Biogen's stronger consensus rating and higher possible upside, research analysts plainly believe Biogen is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Amgen 2 Sell rating(s) 11 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.33 SummaryAmgen beats Biogen on 13 of the 17 factors compared between the two stocks. Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.16B$3.00B$5.48B$9.72BDividend YieldN/A2.28%4.59%4.13%P/E Ratio12.2417.0529.7724.63Price / Sales1.94347.15453.22102.60Price / Cash5.6540.7324.8127.99Price / Book1.128.898.595.76Net Income$1.63B-$54.75M$3.26B$264.95M7 Day Performance-3.68%-2.71%-0.32%-0.01%1 Month Performance-4.63%4.43%2.14%1.27%1 Year Performance-36.33%19.64%44.52%26.11% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.9113 of 5 stars$128.00-2.0%$185.63+45.0%-36.6%$19.16B$9.68B12.247,605Analyst RevisionAMGNAmgen4.567 of 5 stars$300.25+1.1%$307.27+2.3%-11.6%$161.40B$33.42B27.3928,000Earnings ReportAnalyst DowngradeGILDGilead Sciences4.6464 of 5 stars$113.89+0.6%$112.36-1.3%+63.5%$141.55B$28.75B23.9617,600Trending NewsEarnings ReportDividend AnnouncementIONSIonis Pharmaceuticals4.489 of 5 stars$43.59+1.3%$59.38+36.2%-12.3%$6.95B$705M-23.711,069MRNAModerna4.4887 of 5 stars$27.58-0.1%$46.11+67.2%-70.0%$10.68B$3.06B-3.675,800PRTAProthena3.2641 of 5 stars$6.87+0.8%$31.50+358.8%-62.7%$369.01M$135.16M-3.30130SAVACassava Sciences2.7472 of 5 stars$2.31+8.7%$54.50+2,264.4%-89.7%$111.35MN/A-1.5430Upcoming EarningsVRTXVertex Pharmaceuticals4.8935 of 5 stars$470.41+1.8%$509.89+8.4%-20.1%$120.63B$11.10B-119.846,100Analyst UpgradeABBVAbbVie4.6948 of 5 stars$197.06+0.9%$212.81+8.0%+4.5%$348.04B$56.33B93.8355,000Positive NewsBMYBristol Myers Squibb4.6268 of 5 stars$45.28+2.4%$57.33+26.6%-1.7%$92.15B$48.30B18.2634,100Positive NewsLLYEli Lilly and Company4.9993 of 5 stars$767.85+0.7%$1,012.56+31.9%-28.7%$727.60B$45.04B62.4747,000Trending NewsEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies Amgen Competitors Gilead Sciences Competitors Ionis Pharmaceuticals Competitors Moderna Competitors Prothena Competitors Cassava Sciences Competitors Vertex Pharmaceuticals Competitors AbbVie Competitors Bristol Myers Squibb Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIIB) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy Elon put $51 million into thisChris Rowe has made legendary calls—Tesla at $13, Nvidia at $40, Bitcoin under $1,000, Amazon at 12 cents. Now...True Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access